ACADEMAB BIOMEDICAL INC.

Area: Government, Academia and Research Institutes

Booth No: M534

Exhibitor Profile

AcadeMab is a clinical-stage leader redefining cancer care by next-generation antibodies. AM-928, utilizes a unique multi-pathway mechanism to eliminate the root causes of tumor recurrence. We are now accelerating preparations for a Phase II trial. Beyond oncology, by leveraging our mRNA-LNP technology, we have developed a Dengue vaccine that eliminates the safety hurdles of existing options. We provide patented GMP-grade cationic lipids as critical APIs for the global nucleic acid drug market.

Brands

First-in-Class cancer therapeutic antibody-AM-928; Next-generation Dengue vaccine; Novel cationic lipids; Human antibody phage display&transgenic mice